EnteroMedics Inc  

(Public, NASDAQ:ETRM)   Watch this stock  
Find more results for ETRM
0.990
+0.020 (2.06%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.93 - 1.00
52 week 0.82 - 21.00
Open 1.00
Vol / Avg. 51,950.00/176,798.00
Mkt cap 7.02M
P/E     -
Div/yield     -
EPS -4.91
Shares 7.09M
Beta 2.21
Inst. own 23%
Feb 17, 2016
Q4 2015 EnteroMedics Inc Earnings Call - 11:00AM EST - Add to calendar
Feb 16, 2016
Q4 2015 EnteroMedics Inc Earnings Release (Estimated) Add to calendar
Dec 17, 2015
EnteroMedics Inc Year-end Company Update Conference Call - Webcast
Nov 19, 2015
EnteroMedics Inc at Canaccord Genuity Medical Technology & Diagnostics Forum
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -6485.42% -
Operating margin -9391.22% -
EBITD margin - -
Return on average assets -145.43% -128.17%
Return on average equity -362.94% -244.84%
Employees 28 -
CDP Score - -

Address

2800 Patton Rd
SAINT PAUL, MN 55113-1100
United States - Map
+1-651-6343003 (Phone)
+1-651-6343212 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Company's initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries.

Officers and directors

Dan W. Gladney President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Gregory S. Lea Chief Financial Officer, Chief Compliance Officer
Age: 62
Bio & Compensation  - Reuters
Scott A. Shikora M.D. Executive Vice President - Medical Affairs and Chief Medical Officer
Bio & Compensation  - Reuters
Nick Ansari Senior Vice President - Sales
Age: 54
Bio & Compensation  - Reuters
Paul Hickey Senior Vice President - Marketing and Reimbursement
Age: 51
Bio & Compensation  - Reuters
Peter M Delange Senior Vice President - Operations and Business Development
Age: 46
Bio & Compensation  - Reuters
Adrianus Donders Senior Vice President - Research and Advanced Development
Age: 61
Bio & Compensation  - Reuters
Katherine S. Tweden Ph.D. Senior Vice President - Research
Age: 54
Bio & Compensation  - Reuters
Tonya Dowd Vice President - Reimbursement
Bio & Compensation  - Reuters
Mark B. Knudson Ph.D. Non-Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters